Crizotinib, an anaplastic lymphoma kinase (ALK)/ROS1/MET proto‐oncogene, receptor tyrosine kinase (MET) inhibitor, was the first targeted agent approved by the US Food and Drug Administration for the treatment of advanced ROS1‐rearanged NSCLC. Here, ROS1 is linked to non-small cell lung carcinoma.